Quintet Private Bank Europe S.A. Sells 1,943 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Quintet Private Bank Europe S.A. reduced its holdings in Thermo Fisher Scientific by 2.6%, selling 1,943 shares, bringing its total ownership to 72,553 shares valued at approximately $29.4 million.
• Insider trading activity saw CAO Joseph R. Holmes sell 385 shares and CEO Marc N. Casper sell 10,000 shares, indicating a potential decrease in confidence from key executives.
• Thermo Fisher Scientific's stock has a current market cap of $181.06 billion, with analysts forecasting average earnings per share of 23.28 for the current fiscal year and an average target price of $592.24.

Quintet Private Bank Europe S.A. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,553 shares of the medical research company's stock after selling 1,943 shares during the period. Thermo Fisher Scientific comprises 1.7% of Quintet Private Bank Europe S.A.'s holdings, making the stock its 15th biggest holding. Quintet Private Bank Europe S.A.'s holdings in Thermo Fisher Scientific were worth $29,417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $30,000. Finally, Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $31,000. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TMO shares. William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Finally, Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $592.24.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last ninety days. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $479.48 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The business's fifty day moving average is $466.86 and its 200 day moving average is $450.58. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a market cap of $181.06 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the business earned $5.37 EPS. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.